TET2 and acute myeloid leukemia: Myeloid malignancies frequently exhibit epigenetic alterations, and subsets of patients with MDS, MPN, and AML have been shown to harbor activating mutations and loss-of-function mutations in master epigenetic regulators such as DNA methyltransferase 3 (DNMT3) and TET-eleven translocation 2 (TET2); the combination of these mutations account for 33% of the somatic mutations identified in AML (Delhommeau et al., 2009;Langemeijer et al., 2009; Tefferi et al., 2009a,b,c; Patel et al., 2012).